The Response of Human Epithelial Cells to TNF Involves an Inducible Autocrine Cascade

Cell

Volumn 124, Issue 6, 2006, Pages 1225-1239

  Janes, Kevin A ^a,b   Gaudet, Suzanne ^a   Albeck, John G ^a   Nielsen, Ulrik B ^c   Lauffenburger, Douglas A ^a,b   Sorger, Peter K ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b USA   (United States)

^c MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 33646036758     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.01.041     Document Type: Article

References (58)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3 (2003) 745-756
2. Anderson G.M., Nakada M.T., and DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4 (2004) 314-320
3. Anzano M.A., Rieman D., Prichett W., Bowen-Pope D.F., and Greig R. Growth factor production by human colon carcinoma cell lines. Cancer Res. 49 (1989) 2898-2904
4. Avruch J. Insulin signal transduction through protein kinase cascades. Mol. Cell. Biochem. 182 (1998) 31-48
5. Ballif B.A., and Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 12 (2001) 397-408
6. Barnhart B.C., and Peter M.E. The TNF receptor 1: a split personality complex. Cell 114 (2003) 148-150
7. Bender K., Gottlicher M., Whiteside S., Rahmsdorf H.J., and Herrlich P. Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV. EMBO J. 17 (1998) 5170-5181
8. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72 (1975) 3666-3670
9. Chailler P., and Menard D. Ontogeny of EGF receptors in the human gut. Front. Biosci. 4 (1999) D87-D101
10. Chen G., and Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 296 (2002) 1634-1635
11. Chen W.N., Woodbury R.L., Kathmann L.E., Opresko L.K., Zangar R.C., Wiley H.S., and Thrall B.D. Induced autocrine signaling through the epidermal growth factor receptor contributes to the response of mammary epithelial cells to tumor necrosis factor alpha. J. Biol. Chem. 279 (2004) 18488-18496
12. Dinarello C.A. Interleukin-1. Cytokine Growth Factor Rev. 8 (1997) 253-265
13. Dinarello C.A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343 (2000) 732-734
14. Downward J. The ins and outs of signalling. Nature 411 (2001) 759-762
15. Dumont J.E., Dremier S., Pirson I., and Maenhaut C. Cross signaling, cell specificity, and physiology. Am. J. Physiol. Cell Physiol. 283 (2002) C2-C28
16. Efron B., and Tibshirani R.J. An Introduction to the Bootstrap (1993), Chapman and Hall, London
17. Fan H., and Derynck R. Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J. 18 (1999) 6962-6972
18. Fransen L., Van der Heyden J., Ruysschaert R., and Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur. J. Cancer Clin. Oncol. 22 (1986) 419-426
19. Garcia-Lloret M.I., Yui J., Winkler-Lowen B., and Guilbert L.J. Epidermal growth factor inhibits cytokine-induced apoptosis of primary human trophoblasts. J. Cell. Physiol. 167 (1996) 324-332
20. Gaudet S., Janes K.A., Albeck J.G., Pace E.A., Lauffenburger D.A., and Sorger P.K. A compendium of signals and responses triggered by prodeath and prosurvival cytokines. Mol. Cell. Proteomics 4 (2005) 1569-1590
21. Glading A., Bodnar R.J., Reynolds I.J., Shiraha H., Satish L., Potter D.A., Blair H.C., and Wells A. Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol. Cell. Biol. 24 (2004) 2499-2512
22. Goll D.E., Thompson V.F., Li H., Wei W., and Cong J. The calpain system. Physiol. Rev. 83 (2003) 731-801
23. Hambek M., Solbach C., Schnuerch H.G., Roller M., Stegmueller M., Sterner-Kock A., Kiefer J., and Knecht R. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res. 61 (2001) 1045-1049
24. Hofmann F., and Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 10 (2005) 1041-1047
25. Izumi H., Ono M., Ushiro S., Kohno K., Kung H.F., and Kuwano M. Cross talk of tumor necrosis factor-alpha and epidermal growth factor in human microvascular endothelial cells. Exp. Cell Res. 214 (1994) 654-662
26. Janes K.A., Albeck J.G., Peng L.X., Sorger P.K., Lauffenburger D.A., and Yaffe M.B. A high-throughput quantitative multiplex kinase assay for monitoring information flow in signaling networks: application to sepsis-apoptosis. Mol. Cell. Proteomics 2 (2003) 463-473
27. Janes K.A., Kelly J.R., Gaudet S., Albeck J.G., Sorger P.K., and Lauffenburger D.A. Cue-signal-response analysis of TNF-induced apoptosis by partial least squares regression of dynamic multivariate data. J. Comput. Biol. 11 (2004) 544-561
28. Janes K.A., Albeck J.G., Gaudet S., Sorger P.K., Lauffenburger D.A., and Yaffe M.B. A predictive systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310 (2005) 1646-1653
29. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
30. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
31. Kobayashi Y., Yamamoto K., Saido T., Kawasaki H., Oppenheim J.J., and Matsushima K. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc. Natl. Acad. Sci. USA 87 (1990) 5548-5552
32. Masui H., Castro L., and Mendelsohn J. Consumption of EGF by A431 cells: evidence for receptor recycling. J. Cell Biol. 120 (1993) 85-93
33. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
34. Micheau O., and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003) 181-190
35. Micheau O., Lens S., Gaide O., Alevizopoulos K., and Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 21 (2001) 5299-5305
36. Micheau O., Thome M., Schneider P., Holler N., Tschopp J., Nicholson D.W., Briand C., and Grutter M.G. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 277 (2002) 45162-45171
37. Nicholson D.W., and Thornberry N.A. Caspases: killer proteases. Trends Biochem. Sci. 22 (1997) 299-306
38. Nielsen U.B., Cardone M.H., Sinskey A.J., MacBeath G., and Sorger P.K. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc. Natl. Acad. Sci. USA 100 (2003) 9330-9335
39. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
40. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2 (2003) 736-746
41. Panja A., Goldberg S., Eckmann L., Krishen P., and Mayer L. The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J. Immunol. 161 (1998) 3675-3684
42. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., Russell W.E., Castner B.J., Johnson R.S., Fitzner J.N., et al. An essential role for ectodomain shedding in mammalian development. Science 282 (1998) 1281-1284
43. Qian H., Hausman D.B., Compton M.M., Martin R.J., Della-Fera M.A., Hartzell D.L., and Baile C.A. TNFalpha induces and insulin inhibits caspase 3-dependent adipocyte apoptosis. Biochem. Biophys. Res. Commun. 284 (2001) 1176-1183
44. Reinhart K., and Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29 (2001) S121-S125
45. Ruan H., and Lodish H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 14 (2003) 447-455
46. Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
47. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306 (2004) 1506-1507
48. Schulze A., Lehmann K., Jefferies H.B., McMahon M., and Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15 (2001) 981-994
49. Sfikakis P.P., and Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr. Opin. Rheumatol. 15 (2003) 380-386
50. Singh P., and Rubin N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 105 (1993) 1218-1237
51. Stampfer M.R., and Yaswen P. Culture systems for study of human mammary epithelial cell proliferation, differentiation and transformation. Cancer Surv. 18 (1993) 7-34
52. Stelling J., Sauer U., Szallasi Z., Doyle III F.J., and Doyle J. Robustness of cellular functions. Cell 118 (2004) 675-685
53. Streetz K., Leifeld L., Grundmann D., Ramakers J., Eckert K., Spengler U., Brenner D., Manns M., and Trautwein C. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 119 (2000) 446-460
54. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., and Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6 (2000) 1024-1028
55. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 10 (2003) 45-65
56. Wiley H.S., Shvartsman S.Y., and Lauffenburger D.A. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol. 13 (2003) 43-50
57. Wu Y., Tewari M., Cui S., and Rubin R. Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J. Cell. Physiol. 168 (1996) 499-509
58. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., Dunstan C., Kollias G., Steiner G., Smolen J., and Schett G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50 (2004) 277-290